Catholic University Industry Academic Cooperation Foundation

Hanlim Pharmaceutical Co., Ltd.

Catholic University Academic Cooperation Foundation

Hye-Jwa Oh

Mi-La Cho

Jin-Ha Park

Geun-Hyeog Lee

Jun-Ki Min

Yun-Ju Woo

Eun-Young Kwak

Seon-Yeong Lee

Joo-Yeon Jhun

Young-Mee Moon

Jun-Geol Ryu

Byong-Sun Choi

Young-Ok Jung

Yang-Mi Her

Se-Wan Park

The present invention provides a method for preventing or treating osteoarthritis comprising administrating rebamipide or a pharmaceutical composition comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier to a subject in need thereof. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.

Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient

The present invention relates to a composition containing PIAS3 as an active ingredient for the prevention or treatment of cancer or immune disease. More specifically, the present invention relates to a composition containing the PIAS3 gene or an expressing protein thereof as an active ingredient for the prevention or treatment of cancer or immune disease, to an immunosuppressant composition, to a method for reducing or inhibiting undifferentiated T cells into Th17 cells using the PIAS3 gene or an expressing protein thereof, and to a method for activating regulatory T cells.

Composition containing PIAS3 as an active ingredient for preventing or treating cancer or immune disease

The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.

Pharmaceutical composition for preventing or treating rheumatoid arthritis, containing rebamipide

Growing community of inventors

Seoul, South Korea

Hye-Jwa Oh